A5058526027- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- T-cell and B-cell Immunology
- CNS Lymphoma Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Virology and Viral Diseases
- Cytomegalovirus and herpesvirus research
- Antenna Design and Analysis
- Full-Duplex Wireless Communications
- Hepatitis B Virus Studies
- Cell Adhesion Molecules Research
- Plant Virus Research Studies
- Parvovirus B19 Infection Studies
- Monoclonal and Polyclonal Antibodies Research
Istituto Superiore di Sanità
2014-2024
Istituti Fisioterapici Ospitalieri
2009-2010
San Gallicano Hospital
2009-2010
Sapienza University of Rome
2003-2005
Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This attributed persistent virus expression reservoirs and cell activation. Of note, CD4+ T cells monocyte-macrophages of virologically-suppressed individuals, there continued multi-spliced transcripts encoding regulatory proteins. Among them, Tat essential for gene either primary infection or reactivation during...
<p>Supplementary Table 3 shows the clinical treatment-related AEs by SOC and study phases.</p>
<p>Supplementary Table 5 summarizes the representativeness of study participants</p>
<p>Supplementary Table 1 shows the active concurrent illnesses at baseline.</p>
<p>Supplementary Table 4 shows the treatment-related laboratory AE by SOC, preferred terms and study phases.</p>
<p>Supplementary Table 2 shows the treatment-related AE numbers by study phases.</p>
The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and safety of biologically active HIV-1 Tat protein administered 7.5 or 30 μg, given 3 5 times monthly, exploring immunological virological disease biomarkers. study duration 48 weeks, however, vaccinees were followed until last enrolled subject reached weeks. Reported are final data up to 144 weeks follow-up. ISS T-002 conducted in 11...
Tat is a key HIV-1 virulence factor, which plays pivotal roles in virus gene expression, replication, transmission and disease progression. After release, extracellular accumulates tissues exerts effects on both the immune system, promoting activation spreading while disabling host defense. In particular, binds Env spikes particles forming entry complex, favors infection of dendritic cells efficient to T via RGD-binding integrins. also shields CCR5-binding sites rendering ineffective...
Although combined antiretroviral therapy (cART) has saved millions of lives, it is incapable full immune reconstitution and virus eradication. The transactivator transcription (Tat) protein a key human immunodeficiency (HIV) virulence factor required for replication transmission. Tat expressed released extracellularly by infected cells also under cART in this form induces dysregulation, promotes reactivation, entry spreading. Of note, anti-Tat antibodies are rare natural infection and, when...
Introduction: Tat, a key HIV virulence protein, has been targeted for the development of therapeutic vaccine aimed at cART intensification. Results from phase II clinical trials in Italy (ISS T-002) and South Africa T-003) cART-treated patients indicated that Tat vaccination promotes return to immune homeostasis reduces virus reservoir. Here we present data 92 vaccinees enrolled ISS T-002 8-year extended follow-up study EF-UP, ClinicalTrials.gov NCT02118168). Results: Anti-Tat antibodies...
Abstract Kaposi sarcoma is a rare angioproliferative disease associated with human herpes virus-8 (HHV-8) infection. frequent and aggressive in HIV-infected people, whereas the classic form (CKS) generally has an indolent course. Notably, all conventional therapies against have only temporary efficacy. We previously shown that indinavir, HIV protease-inhibitor direct antiangiogenic antitumor activity, safe effective patients early CKS, effects are less prominent advanced disease, probably...
Hemorrhagic cystitis (HC) is a well-known complication after allogeneic bone marrow transplant (BMT) and can be related to adenovirus or human polyomavirus BK (BKV) infections. In this study group of 20 patients BMT has been examined. urine samples were analysed for the presence Adenovirus BKV DNA by means polymerase chain reaction (PCR). 5/20 developed HC BMT. The in was evident 3/15 without 5/5 with HC. 2/5 HC-patients not found therapy Cidofovir Ribavirin. search all negative. analysis...
Previous work has shown that the Tat protein of Human Immunodeficiency Virus (HIV)-1 is released by acutely infected cells in a biologically active form and enters dendritic upon binding its arginine-glycine-aspartic acid (RGD) domain to α5β1, αvβ3, αvβ5 integrins. The up-regulation/activation these integrins occurs endothelial exposed inflammatory cytokines are increased HIV-infected individuals, leading cell dysfunction. Here, we show cytokine-activated selectively bind rapidly take up...
The distribution of DNA BK and JC human polyomaviruses (BKV JCV) was investigated in samples from autopsies different organs 2 groups patients: Human Immunodeficiency Virus −1 (HIV) positive negative. Samples various were analysed by a nested polymerase chain reaction (PCR) for the non-coding control VP1 regions both viruses. results obtained showed that BKV present males females with higher prevalence HIV-positive subject (spleen: 33%; kidney: 44%; brain: 22%, uterine cervix:100%; prostatic...
BackgroundLow-level HIV viremia originating from virus reactivation in reservoirs is often present cART treated individuals and represents a persisting source of immune stimulation associated with sub-optimal recovery CD4+ T cells. The HIV-1 Tat protein released the extracellular milieu activates cells latent HIV, leading to production release. However, relation anti-Tat immunity residual viremia, persistent activation T-cell dynamics has not yet been defined.MethodsVolunteers enrolled...
<p>Supplementary Table 5 summarizes the representativeness of study participants</p>
<p>Supplementary Table 1 shows the active concurrent illnesses at baseline.</p>
<p>Supplementary Table 2 shows the treatment-related AE numbers by study phases.</p>
<p>Immunological parameters in participants that entered the maintenance phase (<i>n</i> = 16). Levels at enrolment, upon induction and during post-therapy follow-up of total lymphocytes absolute number (10<sup>3</sup> cells/μL; <b>A</b>), CD4<sup>+</sup> (<b>B</b>) CD8<sup>+</sup>, (<b>C</b>) T-cell (cells/μL), CD4<sup>+</sup>/CD8<sup>+</sup> ratio (<b>D</b>), B-...
<p>Active MMP-2, CEC, and EPC levels NK activity in participants that entered the maintenance phase (<i>n</i> = 16). Shown are (cells/mL) at enrolment, upon induction, during maintenance, post-therapy follow-up of active MMP-2 (<b>A</b>), CEC (<b>B</b>), (<b>C</b>), NK-cell against K562 (<b>D</b>) or BCBL-1 targets (<b>E</b>) as % lysis. Data presented box plots. Wilcoxon signed rank sum test for paired data...
<p>Immunological parameters in participants that entered the maintenance phase (<i>n</i> = 16). Levels at enrolment, upon induction and during post-therapy follow-up of total lymphocytes absolute number (10<sup>3</sup> cells/μL; <b>A</b>), CD4<sup>+</sup> (<b>B</b>) CD8<sup>+</sup>, (<b>C</b>) T-cell (cells/μL), CD4<sup>+</sup>/CD8<sup>+</sup> ratio (<b>D</b>), B-...